Robert A. Freedman

Co-Chair, Capital Markets & Public Companies

Partner, Corporate  

San Francisco 650.335.7292


Robert Freedman is co-chair of the Capital Markets & Public Companies​ group and provides corporate and securities law services to late stage and public technology and life sciences companies. He leads initial public offerings and follow-on offerings of equity and debt, and focuses on advising boards and management on corporate and securities law compliance and disclosure matters. Rob has represented issuers and underwriters in securities offerings by public companies for over 20 years. Rob also concentrates on mergers and acquisitions and private financings for public companies.​​

Chambers USA ranks Rob a top capital markets lawyer, with clients noting, “Rob's greatest strength is his sound legal judgment borne out by years of experience. This provides him the ability to move discussions to common middle ground and help create bridges between the company and other parties. In 2019, he was honored in US News for his excellence in Securities and Capital Markets Law as well as Corporate Law. Additionally, Rob has been recommended by The Legal 500 for his individual practice and role as co-chair of Fenwick’s corporate and securities practice, which was recognized as a team of “highly knowledgeable and flexible technology sector specialists."

Clients Rob has represented in initial public offerings include:

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Dermira
  • Dexcom
  • Loxo Oncology
  • Morphic Holding
  • Piper Jaffray & Co.
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Sutro Biopharma
  • Stoke Therapeutics 
  • Upwork

Clients Rob has represented in merger and acquisition and tender offer transactions include:

  • Loxo Oncology’s acquisition by Eli Lilly
  • OncoGenex Pharmaceuticals’ merger with Achieve Life Science
  • Castlight Health’s acquisition of Jiff
  • Corium's acquisition by Gurnet Point Capital
  • KalVista Pharmaceuticals’ acquisition of Carbylan Therapeutics
  • Dexcom’s acquisition of SweetSpot Diabetes Care
  •’s acquisition by
  • Alpha Innotech’s acquisition by Cell Biosciences
  • Data Domain’s acquisition by EMC
  • Cisco Systems’ acquisition of WebEx Communications
  • Macromedia’s merger with Adobe

Rob is the co-chair for the Practising Law Institute’s “How to Prepare an Initial Public Offering” program.

Prior to law school, Rob was a banker for Manufacturers Hanover Trust in New York.​​​​​​​